α-Galactosylceramide Analogs with Weak Agonist Activity for Human iNKT Cells Define New Candidate Anti-Inflammatory Agents by Bricard, Gabriel et al.
a-Galactosylceramide Analogs with Weak Agonist
Activity for Human iNKT Cells Define New Candidate
Anti-Inflammatory Agents
Gabriel Bricard
1, Manjunatha M. Venkataswamy
1, Karl O. A. Yu
1, Jin S. Im
1, Rachel M. Ndonye
3,
Amy R. Howell
3, Natacha Veerapen
4, Petr A. Illarionov
4, Gurdyal S. Besra
4, Qian Li
5¤, Young-Tae Chang
5,
Steven A. Porcelli
1,2*
1Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, United States of America, 2Department of Medicine, Albert
Einstein College of Medicine, Bronx, New York, United States of America, 3Department of Chemistry, University of Connecticut, Storrs, Connecticut, United States of
America, 4School of Biosciences, University of Birmingham, Edgbaston, United Kingdom, 5Department of Chemistry, National University of Singapore, Singapore
Bioimaging Consortium, Agency for Science, Technology and Research (A*STAR), Biopolis, Singapore
Abstract
CD1d-restricted natural killer T cells with invariant T cell receptor a chains (iNKT cells) are a unique lymphocyte subset that
responds to recognition of specific lipid and glycolipid antigens. They are conserved between mice and humans and exert
various immunoregulatory functions through their rapid secretion of a variety of cytokines and secondary activation of
dendritic cells, B cells and NK cells. In the current study, we analyzed the range of functional activation states of human iNKT
cells using a library of novel analogs of a-galactosylceramide (aGalCer), the prototypical iNKT cell antigen. Measurement of
cytokines secreted by human iNKT cell clones over a wide range of glycolipid concentrations revealed that iNKT cell ligands
could be classified into functional groups, correlating with weak versus strong agonistic activity. The findings established a
hierarchy for induction of different cytokines, with thresholds for secretion being consistently lowest for IL-13, higher for
interferon-c (IFNc), and even higher for IL-4. These findings suggested that human iNKT cells can be intrinsically polarized to
selective production of IL-13 by maintaining a low level of activation using weak agonists, whereas selective polarization to
IL-4 production cannot be achieved through modulating the strength of the activating ligand. In addition, using a newly
designed in vitro system to assess the ability of human iNKT cells to transactivate NK cells, we found that robust secondary
induction of interferon-c secretion by NK cells was associated with strong but not weak agonist ligands of iNKT cells. These
results indicate that polarization of human iNKT cell responses to Th2-like or anti-inflammatory effects may best be achieved
through selective induction of IL-13 and suggest potential discrepancies with findings from mouse models that may be
important in designing iNKT cell-based therapies in humans.
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Introduction
Natural killer T cells (NKT cells) were originally defined as T
cells that constitutively expressed NK-associated receptors in naı ¨ve
mice [1–4]. Subsequent classification of subsets with these general
properties has defined a major population known as type 1 or
invariant NKT cells (iNKT cells), that express an invariant TCRa
chain (Va14Ja18 in mouse, Va24Ja18 in human) which is paired
with TCRb chains of limited diversity. iNKT cells recognize lipids
and glycolipids presented by the conserved non-polymorphic
MHC class I-like molecule, CD1d, and recognize natural self or
microbial glycolipids as well as a range of synthetic glycosylcer-
amides [5]. The prototypic synthetic iNKT cell antigen is a
synthetic a-galactosylceramide (aGalCer) known as KRN7000,
which contains a C18 phytosphingosine linked with a saturated
C26 N-acyl chain, has been extensively studied as a model antigen
for iNKT cells in humans, as well as mice and other animal
models, including rats and nonhuman primates [6–9].
Upon stimulation with KRN7000, iNKT cells exert multiple
immuno-regulatory functions due in part to their rapid secretion of
a wide range of cytokines. iNKT cells have a striking capacity to
concurrently produce cytokines that are classically associated with
both Th1 responses (e.g., IFNc, TNFa) and Th2 responses (IL-4,
IL-5, IL-13). Furthermore, their activation leads to induction of
DC maturation, transactivation of NK cells and help to B cells
[1;10]. Depending on the disease model considered, KRN7000-
stimulated iNKT cells have shown an ability to modulate or
improve immune responses in the context of tumors, microbial
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parameter in the generation of iNKT cell-driven inflammatory
responses is the ability of iNKT cells to stimulate DCs in a
CD40L-dependent manner, which activates DCs to secrete IL-12
that can then stimulate NK cells to secrete IFNc [11] or to exert
tumoricidal activity [12]. Additional physiological functions of
iNKT cells have been defined recently based on the fact that
iNKT cells show a weak and CD1d-dependent reactivity to self
lipid(s) (also referred to as ‘‘autoreactivity’’). This is especially
characterized by IL-13 and GM-CSF secretion, as shown most
clearly for human iNKT cells upon coculture with monocytes [13]
and DCs [14]. In the context of microbial infection, a higher
degree of iNKT cell activation is achieved upon self-lipid
recognition together with APC-derived IL-12 and IL-18, or type
I Interferon co-stimulation, leading to a strong IFNc production
[13;15;16].
Because of the multiple immunological activities of iNKT cells,
there have been intensive efforts recently to identify structural
analogs of aGalCer that have the ability to selectively stimulate a
limited range of iNKT cell functions. A particular emphasis has
been on obtaining glycolipid agonists that stimulate a more
restricted range of cytokine secretion compared to the mixed Th1
and Th2 type response that results from iNKT cell activation by
KRN7000. These studies have provided several well characterized
examples of variants of aGalCer that have the ability to skew
mouse iNKT cell responses to either pure Th2 cytokine
production and immunosuppressive activity or predominantly
Th1 cytokine production and pro-inflammatory activity. Two
prototypic Th2 polarizing agonists have been identified to date.
These are an aGalCer analogue known as OCH, which contains a
substantially truncated phytosphingosine chain (C9) and a slightly
shorter N-acyl chain (C24) compared to KRN7000, and a
potentially more potent Th2 skewing analog of aGalCer
designated C20:2 because of its 20 carbon di-unsaturated N-acyl
chain. These Th2 biasing analogs induce similar IL-4 production
but much weaker and more transient IFNc production when
injected systemically into mice when compared to KRN7000. This
appears to result mainly from a failure of these analogs to induce
the transactivation of NK cells and their production of IFNc as a
secondary consequence of iNKT cell activation [11;17]. In
contrast, the C-glycoside analog of KRN7000 was identified in
mouse as Th1 polarizing compound that induces little IL-4
secretion but strong and sustained IFNc production [18]. This
compound does not induce detectable IL-4 production from
mouse iNKT cells but leads to pronounced NK cell transactivation
and IFNc secretion [19]. Both OCH and the C20:2 analog have
shown superior therapeutic effects compared to non-Th2-biasing
activators such as KRN7000 when studied in various mouse
models of autoimmune or inflammatory disease [20–23]. Similarly
as predicted, the strongly Th1-biasing C-glycoside analogue has
shown superior therapeutic effects in mouse models of cancer and
chronic infection [18].
The mechanisms accounting for the cytokine biasing effects of
aGalCer analogs such as OCH, C20:2 and C-glycoside are
incompletely understood and remain a major focus for ongoing
studies. Initial studies revealed that, in contrast to KRN7000,
OCH weakly induced expression of c-rel, which is necessary for
mouse iNKT cells to secrete IFNc [24], and lower CD40L
expression, IL-12 production and NK cell transactivation [11].
Recently, we demonstrated that, unlike KRN7000 which requires
lysosomal loading onto CD1d, the C20:2 analog and other Th2
skewing analogs like OCH were characterized by a rapid and
direct loading of cell surface CD1d proteins [17]. Another recent
report showed that an active mechanism prevents Th2-polarizing
analogs from being loaded in lysosomal compartments, thereby
allowing them to be more selectively loaded at the cell surface
[25]. This correlated with exclusion of the resulting CD1d/
glycolipid complexes from detergent resistant microdomains of the
APC plasma membrane [26]. Very recently, the ability of the C-
glycoside to stimulate a Th1-polarized response following iNKT
cell activation has been attributed to its more sustained
presentation compared to KRN7000, despite the finding that
iNKT cell TCRs showed a much lower binding avidity to
complexes of C-glycoside bound to mCD1d [27].
To date, OCH has shown weak or no detectable ability to
stimulate human iNKT cells [20;26]. Similarly, the C-glycoside
analogue is only weakly stimulatory for human iNKT cells in
culture [28;29]. In contrast, the C20:2 analogue is a strong agonist
for human iNKT cells, and the cytokine secretion profile of cloned
human iNKT cell lines is similar between C20:2 and KRN7000
[17;20;26;30;31]. These findings raise the question of whether
analogs identified in the mouse model as selective activators of
iNKT cell function will have the same or similar activities in
humans, which is obviously an issue of major importance for
attempts to develop agents of clinical utility. Given the above
considerations and also several reports suggesting that subtle
discrepancies in iNKT cell reactivity can be observed between
mouse and human [17;20;26;30–33], there is a need for additional
work comparing the quality of responses to iNKT cell antigens
that stimulate responses in both mouse and human. In the current
study, we have focused on the functional reactivities of human
iNKT cells to KRN7000 and an extended panel of synthetic
aGalCer analogs, including the previously identified cytokine
polarizing compounds C20:2, OCH and C-glycoside, defined in
the mouse system, as well as additional novel analogs. Analysis of
the profile of cytokines secreted by cloned human iNKT cell lines
over a wide range of glycolipid concentrations allowed the
definition of strong and weak agonists. An important observation
was that human iNKT cells secretion of IFNc was induced at a
lower degree of activation compared to induction of IL-4
secretion. Moreover, the design of a new in vitro assay, aiming to
measure the ability of aGalCer-stimulated iNKT cells to
transactivate other leukocytes, revealed that a strong iNKT cell
agonist was necessary to induce NK cells to secrete IFNc.
Conversely, cytokine profiling indicated that weak glycolipid
agonists had the best potential to induce a Th2-like quality of the
direct iNKT cell response, because of the selective secretion of IL-
13 and little or no IFNc. These weak iNKT cell agonists may thus
represent potential anti-inflammatory immunomodulators with
potential applications in human iNKT cell-based therapy of
inflammatory or autoimmune diseases.
Materials and Methods
Antibodies and staining reagents
For flow cytometric analysis, 6B11 (Va24Ja18 specific) and
mAbs specific for human CD3, CD4, CD8a, CD19, CD40L
(CD154), CD56, CD69, GM-CSF & IFNc were obtained from
BD Biosciences. IL-4 and IL-13 specific mAbs were from
Biolegend. Va24 (C15) and Vb11 (C21) specific mAb were from
Immunotech. For antibody blocking in culture assays, non-specific
isotype matched control, IL-2, IFNc, IL-12p70 and CD40L
specific mAbs without preservatives were obtained from BD
Biosciences and IL-18 specific mAb from Medical & Biological
Laboratories (MBL, Nagoya, Japan). Phycoerythrin and allophy-
cocyanin labeled human CD1d tetramers were prepared in our
laboratory as previously described [34]. Curves of tetramer
equilibrium binding constants and graphs were plotted using the
Weak Human iNKT Cell Agonists
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using the function non-linear fit (hyperbola, one binding site).
Generation and cultivation of iNKT cell clones
The use of healthy donor PBMC (Peripheral Blood Mononu-
clear Cells) was reviewed and accepted by the Einstein
Institutional Review Board. Written informed consent was
obtained from all blood donors. CD3
+Va24
+Vb11
+ were sorted
from healthy donor PBMC using a MoFlo cell sorter (Beckman
Coulter, Inc.) to deposit individual iNKT cells in wells of 96-well
plates. Cells were expanded by PHA stimulation (PHA-P, Difco,
Detroit, MI, which was reconstituted according to the supplier’s
instructions and used at a final dilution of 1:2,000), in the presence
of irradiated allogeneic PBMCs (3000 rad) and IL-2 at 250 IU/
mL (Chiron). Culture medium was RPMI-1640 containing L-
Glutamin (Gibco-BRL) supplemented with 10% fetal calf serum
(FCS; Atlanta Biologicals) and 10 mM HEPES, 50 mM2 -
mercaptoethanol, 1 mM Sodium Pyruvate and 1% nonessential
amino acids mixture (all from Gibco-BRL). Cultures were
maintained at 37uC in a humidified 5% CO2 incubator and were
restimulated every 3 weeks and expanded by splitting and feeding
with fresh medium with 250 IU/ml IL-2 as required. To avoid
residual stimulation from PHA, the clones were tested in
functional assays at least 2 weeks after the last PHA stimulation,
when cells returned to a resting state, characterized by arrest of
divisions and loss of their tear-drop shape. The TCR specificity of
clones was validated by FACS using staining with mAbs specific
for CD3, Va24, Vb11 and the invariant iNKT cell TCR chain
(6B11), and the cell surface phenotype was determined by staining
with CD4 and CD8a specific mAbs.
Glycolipid preparation
All glycolipids used in this study were synthesized as previously
described [17;34–36]. Glycolipids were initially dissolved in 100%
DMSO at concentrations between 2 and 20 mM and then diluted
to 500 mM in DMSO. Glycolipids dissolved in DMSO were stored
frozen at -20uC. Immediately prior to use, the stock solutions were
heated to 80uC for 10 minutes, followed by 10 minutes of
sonication in a water bath sonicator (Branson model 2510, Fisher
Scientific), and then mixed by high speed vortexing to ensure full
dissolution of the glycolipids. For in vitro assays, the 500 mM
glycolipid stocks in DMSO were diluted directly into prewarmed
(37uC) culture medium with vigorous mixing and 10 minutes of
sonication. This was followed by serial dilutions in 37uC medium
with vigorous mixing.
Cytokine ELISA
Capture ELISA assays were used for measurement of cytokine
responses of human iNKT cells to aGalCer analogs. One day
prior to the experiment, CD1d transfected HeLa cells [37] were
plated at 25610
3 cells/well in 100 mL of medium in flat-bottom 96
well plates. Glycolipids were then added in 100 mL of medium to
give final concentrations ranging from 0.05 to 10
4 nM. The APCs
were incubated for approximately 18 hours with the glycolipids
and then irradiated (10,000 Rad) and washed twice with PBS prior
to addition of 25610
3 iNKT cells well in 300 mL. Supernatants
were harvested after 24 hours of co-culture and stored frozen at -
20uC. After thawing, aliquots of the supernatants were assayed for
specific cytokines by ELISA using capture and biotin-labeled
detection antibody pairs specific for GM-CSF, IL-2, IL-4, IL-
12p70 and IL-13 (all obtained from BD Biosciences), IFNc
(Thermo-Scientific) or IL-18 (MBL). Specific signals were
developed using HRP- conjugated streptavidin (BD Biosciences)
and Turbo TMB substrate (Thermo-Scientific). Supernatants were
tested pure and/or diluted to give values within a quantitative
linear standard curve generated with recombinant cytokines.
Curves of dose-dependent cytokine responses and graphs were
plotted using the Graphpad Prism Software. EC50 values were
calculated using the function log (agonist) response with variable
slope, and statistical analyses were carried out using the same
software. To calculate concentration-dependent cytokine ratios,
IL-4/IFNc and IL-13/IFNc ratios were calculated using cytokine
values from which background levels (i.e. levels in cultures
receiving DMSO vehicle alone) were subtracted. Ratios were
calculated by dividing IL-4 or IL-13 concentrations in pg/mL by
IFNc concentration in ng/mL.
In vitro transactivation assay and detection of CD40L
expression
iNKT cells were stained for 5 minutes with 1–20 mM of CFSE
(Molecular probes) and 5% FCS in PBS and washed twice. As a
positive control, a fraction of CFSE-labeled iNKT cells were
preactivated for 30 minutes with 1 mg/mL of PMA and 250 ng/
mL of Ionomycin (Sigma-Aldrich) in culture medium and
extensively washed. The experiment was initiated by adding
CFSE-labeled unstimulated or PMA/Ionomycin-preactivated
iNKT cells to freshly prepared PBMC pulsed with vehicle or
aGalCer analogs at the indicated concentrations and at an iNKT/
PBMC ratio of 1/10 or 1/40. Supernatants and cells were
harvested from parallel conditions after the indicated time of co-
culture. For intracellular cytokine staining, brefeldin A (Golgiplug,
BD Biosciences) was added 4 h before harvesting the cells, which
were fixed with 1% paraformaldehyde and permeabilized with
0.1% saponin (Sigma-Aldrich) prior to mAb staining. Experiments
with blocking antibodies were performed with 10 mg/mL of
preservative-free mAbs, including isotype matched control, anti-
IL-2, anti-IL-12, anti-IFNc and anti-CD40L (all from BD
Biosciences) or anti-IL-18 (MBL). For detection of CD40L
expression by iNKT cells, co-cultures of iNKT and PBMC were
prepared as above, except that monensin (Golgistop, BD
Biosciences) and fluorescent CD40L specific mAb (1/10 or 1/20
final dilution) were added at the beginning of the experiment, as
previously described [38].
Results
Identification of strong and weak glycolipid agonists for
human iNKT cells
To characterize the quality of human iNKT cell responses to
KRN7000 and to identify potential Th1 or Th2 skewing analogs,
we assessed the reactivity of human iNKT cell clones to KRN7000
and multiple aGalCer analogs. The aGalCer analogs chosen for
analysis included the previously described and characterized
sphingosine chain truncated OCH compound [21], the C-
glycoside variant of KRN7000 [18], and the Th2 cytokine biasing
aGalCer C20:2 and C20:4 analogs [17;20;26] (Figure 1). In
addition, a large panel of other less extensively characterized
aGalCer analogs with a range of structural variations in their N-
acyl chains were screened, and five novel aGalCer analogs were
selected on the basis of their ability to stimulate ex vivo expansion of
iNKT cells from PBMCs [35]. The analogs selected for detailed
study included Lyso-aGalCer (with free amino instead of an amide
linked acyl group on the phytosphingosine base) and aGalCer
analogs with aromatic or adamantanoyl amide linked groups
(Figure 1).
As previously observed, some iNKT cell clones displayed
variable reactivity to CD1d-transfected APCs in the absence of
exogenously added synthetic antigen, which manifested as
Weak Human iNKT Cell Agonists
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production (Supplementary Figure S1). This pattern of ‘‘auto-
reactivity’’ was CD1d-dependent, since the same iNKT cells did
not react to mock-transfected HeLa cells (not shown), and
suggested that iNKT cells can recognize lipid(s) derived from
HeLa APC. The assessment of iNKT cell reactivity to a wide
range of concentrations of KRN7000 (0.05 nM to 100 nM)
revealed that the most sensitive indicator of an Ag-dependent
response of iNKT cells among the cytokines measured was IL-13
production, which was induced at very low KRN7000 concentra-
tion (#0.1 nM), and reached maximal production at a concen-
tration of approximately 1 nM (Figure 2). IFNc was induced with
a similar profile, but required about a 1 log higher concentration
of KRN7000 to be induced and to reach a plateau response.
Interestingly, IL-4 production showed the highest threshold
concentration of KRN7000 for induction of detectable secretion,
and induction of this response was saturated only at very high
KRN7000 concentrations in the mM range (not shown). In
addition, the maximal levels of secreted cytokines in pg/mL were
lower for IL-4 compared to IL-13, and even lower compared to
IFNc.
Responses of iNKT cell clones to the C20:2 analogue were
associated with similar or slightly weaker dose-dependent cytokine
profiles compared to KRN7000 (Figure 2A and not shown),
indicating a potency or an agonistic activity comparable to
KRN7000, as previously suggested [20;26;30;31]. A substantially
lower iNKT cell response was observed with the C20:4 analog, as
well as with the lyso- and toluenoyl- aGalCer analogs (Figure 2B).
All iNKT cell clones tested displayed a much weaker reactivity to
OCH, and relatively high concentrations (.10 nM) of this analog
were required to induce detectable IL-13 production or weak
IFNc secretion (Figures 2A and 2B). OCH mediated-induction of
IL-4 was minimal with all clones tested. A pattern similar to that of
OCH was observed with the N-aromatic branched analogs. The
data shown in Figure 2 were generated with a CD4
+ iNKT cell
clone (HDD3) and are representative of another CD4
+ clone
(HDD11), as well as a double negative (DN, HDE3) and CD8a
+
clone (HDA7). Large cytokine titrations for the DN clone and the
CD8a
+ clones are presented in supplementary Figure S2 and S3,
respectively. The other clones tested displayed a comparable
sigmoidal response to analogs, with a similar strong agonist activity
for KRN7000 or the C20:2 analog; and a weak agonist activity for
the remaining analogs. However, the clones differed in their
degree of ‘‘autoreactivity’’ (Supplementary Figure S1) and in the
magnitude of cytokines they were able to secrete, i.e. the DN or
the CD8a
+ clones systematically produced maximal amounts that
were lower than the amounts produced by the CD4+ clones
(Figure2, Supplementary Figure S2/S3 and data not shown).
Surprisingly, only a fraction of the iNKT cell clones tested
displayed a weak, but detectable, reactivity to the C–glycoside
analog, which was comparable to the response to OCH, with
primarily IL-13 production and a limited induction of IFNc
(Supplementary Figure S4) and data not shown). Two clones out of
six clones tested displayed a detectable reactivity to the C–
glycoside analog. Altogether, the patterns of cytokine secretion
observed over a large range of antigen concentrations suggested
that iNKT cell agonists have variable potency or agonistic ability,
with some analogs being strong agonists while other are
intermediate or weak agonists.
CD1d-transfected Hela cells might not be representative of the
presentation by DCs, so we performed a comparative analysis,
with more limited analog concentrations, between Hela-CD1d
cells and monocyte-derived DC (Supplementary Figure S5).
Comparable cytokine profiles were observed between Hela-
CD1d cells and DC, with IL-13 being induced at the lowest Ag
stimulation and with KRN7000 and C20:2 analogs being strong
agonists while other behaved as intermediate or weak agonists.
However we observed a higher cytokine levels produced upon
stimulation with Hela cells, which can be explained by a higher
CD1d expression.
Characterization of strong versus weak iNKT cell agonists
using CD1d tetramers
To characterize in more detail the iNKT cell TCR recognition
of aGalCer analogs presented by human CD1d, we generated
soluble and fluorescent tetrameric hCD1d molecules loaded with
each of the glycolipid analogs. Staining of iNKT cell clones
showed that tetramers could be reliably generated with all
compounds, with the exception of tetramers loaded with the
lyso-aGalCer analog, which failed to detectably stain any of our
iNKT cell clones. This was similar to the previously reported
failure of mouse CD1d tetramer loaded with lysosulfatide to bind
detectably to murine non-invariant and sulfatide specific NKT
cells, despite a clear reactivity to this lipid upon presentation by
APCs [39;40]. Tetramers loaded with OCH and C-glycoside
provided only a weak staining intensity of a subset of iNKT cell
clones tested (Supplementary Figure S2 and not shown), as we
previously observed [17;20]. To quantitate their binding avidities
to iNKT cell TCRs, we used titration of analog-loaded hCD1d
tetramers to determine equilibrium dissociation constants (KD),
which are inversely proportional to avidity (Figure 3A and 3B).
Human iNKT TCRs displayed a strong avidity for KRN7000,
C20:2 and C20:4 analogs in complex with hCD1d, as previously
described [17;20;26], with KD values in the 2–5 nM range.
However, all analogs with N-aromatic branching displayed a
weaker avidity, as they generated lower intensities of tetramer
staining and higher KD, in the 30–80 nM range (Figure 3A and B),
consistent with functional studies identifying them as weak iNKT
cell agonists compared to KRN7000. In addition, when tetramers
were loaded using a range of glycolipid to CD1d ratios, we found
that tetramers were efficiently loaded at a 25–50 fold lipid excess
for KRN7000 and for toluenoyl-, bromobenzoyl- and adamanta-
noyl-derivatives of aGalCer. However, a much higher lipid excess
was necessary to achieve optimal loading with difluorobenzoyl
analog (Figure 3C). These findings suggested that all of the N-
aromatic branched compounds studied had weak iNKT TCR
avidity, and the difluorobenzoyl analog also had weak binding to
hCD1d.
Our panel of clones might be limited to iNKT cells able to
expand upon PHA stimulation and might be representative of a
fraction only of the iNKT cell repertoire. To demonstrate that the
iNKT cell cross-reactivity between KRN7000 and aGalCer
analogs was not limited to the clones tested, but valid for the
majority of iNKT cells, we performed ex vivo tetramer staining of
Figure 1. Structure of aGalCer analogs. Structures and nomenclature of synthetic aGalCer analogs used in this study. All analogs contain the
same phytosphingosine core of KRN7000 with 18 carbons and 2S, 3S, 4R stereochemistry, except OCH which has a shorter phytosphingosine (C9) and
shorter N-acyl chain (C24). The C-glycoside analog (C-Gly) is modified by a carbon linkage between the galactosyl residue and the ceramide moiety.
Other structural analogs are modified with either no N-branching (Lyso), poly-unsatured N-acyl chains (C20:2 and C20:4) or with N-aromatic groups
(Toluenoyl (Tol), Difluorobenzoyl (DFB), Bromobenzoyl (BB) or Adamantanoyl (AD)).
doi:10.1371/journal.pone.0014374.g001
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(Figure 4A). Comparable iNKT cell frequencies were observed
between staining with Va24Ja18 specific Ab 6B11 and KRN7000-
, C20:2- and C20:4-loaded tetramers (Figure 4B). The frequencies
of iNKT cells measured using tetramers loaded with N-aromatic
branched analogs were lower in some or all PBMCs tested. A
lower detection might be explained by weaker efficiency of
staining, since lower MFI values were also seen with iNKT cell
clones stained with tetramers loaded with these glycolipids.
However, tetramer staining of PBMCs suggested that at least a
Figure 2. Cytokine responses of human iNKT cell clones to a dose range of aGalCer analogs. CD1d-transfected HeLa cells were incubated
overnight with increasing concentrations of KRN7000 and aGalCer analogs (ranging from 0.05 to 100 nM for KRN7000, C20:2 and C20:4 for analogs;
and 39 nM to 10 mM for other analogs; abbreviations for glycolipids as indicated in Figure 1) and then used as APC for iNKT cell stimulation. After
24 h of co-culture, supernatants were harvested, and cytokine levels were measured by ELISA. The sensitivity of detection was 27.4 pg/mL for IL-4
and 82.3 pg/mL for IL-13 and IFNc. The data shown were generated with a CD4
+ iNKT cell clone (HDD3) and are representative of another CD4
+ clone
(HDD11), as well as a double negative (DN, HDE3) and CD8a
+ clone (HDA7). (A) Dose-response curves are presented for IFNc, IL-4 and IL-13 (top to
bottom panels respectively). Mean values measured from triplicate wells are indicated, and standard deviations are shown with brackets. Symbols for
each glycolipid are indicated in the legend. No iNKT cell reactivity was detected with mock-transfected HeLa cells (not shown). (B) HDD3 iNKT cell
clone cytokine responses measured for all glycolipids using 100 nM of KRN7000, C20:2 and C20:4 (black bars) or 10000 nM (10 mM) of other analogs
(cross hatched bars). This clone did not display detectable reactivity to the C-glycoside (Supplementary Figure S2).
doi:10.1371/journal.pone.0014374.g002
Weak Human iNKT Cell Agonists
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tetrameric CD1d complexes loaded with weak agonist glycolipids
with N-aromatic branching.
Hierarchy of anti-inflammatory versus pro-inflammatory
iNKT cell cytokine induction
A strikingly consistent feature of our analysis of the responses to
various aGalCer analogs was the induction of IL-13 secretion at a
lower degree of activation when compared to induction of the other
cytokines tested. This was readily observed by examining EC50
values of the various ligands for production of each cytokine
(Figure 5A). Indeed, regardless of the potency of the glycolipid, the
EC50 values for IL-13 were in all cases lower than the EC50 values
for IFNc, and even lower than those for IL-4 (Figure 5A). This
suggested that human iNKT cells do not polarize in an antigen-
dependent manner, but more likely do so in a manner that depends
Figure 3. Characterization of human iNKT cell TCR interactions with analog-loaded tetramers. (A) iNKT cell clones were stained with
titrated amounts of hCD1d tetramers loaded with the indicated glycolipids (abbreviations as in legend to Figure 1), and the measured MFI values are
plotted for selected glycolipids. (B) The equilibrium dissociation constants (KD, inversely proportional to TCR avidity) were determined as the
concentrations of tetramers required to yield 50% of maximal binding. Data shown were obtained using the CD4
+ iNKT cell clone HDD3, and similar
results (not shown) were obtained with a second CD4
+ clone (HDD11) and a CD4
28
2 double negative iNKT cell clone (HDE3). (C) Analysis of iNKT cell
clones labeled with 20 nM of hCD1d tetramers which were loaded with variable excesses of analog to constant hCD1d (25 to 1000 fold molar excess
of glycolipid to hCD1d protein). The measured MFI values were normalized as the percent of the maximum staining intensity obtained with each
analog loaded tetramer. Data presented were generated with HDD3 (CD4+) iNKT cell clone, and similar results (not shown) were obtained with HDE3
(DN) clone.
doi:10.1371/journal.pone.0014374.g003
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variations in IL-13/IFNc ratios which indicated a more pro-
nounced Th2-type bias at lower glycolipid concentrations, which
wasnotevidentforIL-4/IFNcratioswhichappearedmoreconstant
(Figure 5B).Altogether,thesedata suggested that humaniNKTcells
can be polarized to IL-13 production with a weak stimulus, whereas
a true polarization to IL-4 without IFNc production may not be
possible. Similar patterns of high IL-13/IFNc ratios at low
activation degrees and stable IL-4/IFNc ratios were also observed
with DCs (Supplementary Figure S6).
Interestingly, iNKT cells with autoreactivity showed high IL-
13/IFNc ratios in absence of synthetic antigen (supplementary
Figure S1 and data not shown), and the highest IL-13/IFNc ratios
were found with a low degree of Ag-dependent activation for all
clones (i.e., at suboptimal doses of agonists) (Figure 5B and
Supplementary Figure S6). Thus, the responses of human iNKT
cell clones induced with weak agonists, or suboptimal doses of
strong agonists, was comparable to the pattern of activation
previously reported in the context of ‘‘autoreactivity’’ in response
to self lipids, especially with regard to the predominant expression
Figure 4. Ex vivo analysis of PBMC with CD1d tetramers loaded with aGalCer analogs. (A) Flow cytometric analyses were performed after
labeling of PBMCs from healthy donors with hCD1d tetramers loaded with each of the indicated glycolipids. Representative dot plots generated with
PBMCs from one normal donor, with the analog tested indicated at the top of each plot and the percentages of tetramer
+ CD3
+ cells indicated in the
top right quadrants. The dot plots show events gating as live lymphocytes (PI negative and FSC/SSC gated lymphocytes). (B) Comparison of tetramer
+
cell frequencies in PBMC from three different donors. The frequencies of cells specifically stained with hCD1d tetramers loaded with the indicated
glycolipids (or vehicle (Veh) only (i.e., DMSO)) are shown as the percentage of total iNKT cells (i.e., cells staining with mAb 6B11
+, specific for the
invariant TCRa chain of iNKT cells). Similar results were obtained for three additional PBMC donors (not shown).
doi:10.1371/journal.pone.0014374.g004
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PLoS ONE | www.plosone.org 8 December 2010 | Volume 5 | Issue 12 | e14374Figure 5. Antigen and dose-dependent cytokine polarization of human iNKT cells. (A) EC50 values (Ag concentration required to obtain
half maximal cytokine response) were calculated for production of the indicated cytokines in response to each of the glycolipid agonists. Values are
presented on a logarithmic scale, and EC50 values of IL-4 for C20:4, OCH, DFB, BB and AD compounds could not be calculated because IL-4 levels did
not reach a plateau and were .10 mM. (B) To show variations in cytokine ratios depending on the analog concentration tested, IL-13/IFNc ratios and
IL-4/IFNc ratios are presented on the bottom and top panel, respectively (calculated as explained in Materials and Methods). Note that ratios could be
calculated only when IL-4 and/or IFNc were detectable and the # symbol indicates ratios which could not be calculated. Concentrations of antigens
are indicated as in figure 2A, with low concentrations tested for KRN7000, C20:2 and C20:4 (1.6, 12.5 and 100 nM, white background bars) and high
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been reported to occur in the context of autoreactivity and
costimulation with IL-12 plus IL-18 [13;15], we examined the
effect of these two cytokines on the responses to weak agonist
glycolipids or suboptimal doses of strong agonists. This showed
that addition of IL-12 plus IL-18 markedly enhanced the IFNc
secretion from such cultures. In contrast, IL-13 secretion was
generally reduced under these conditions, while IL-4 and GM-
CSF secretion were only modestly increased or not affected
(Supplementary Figure S7). Altogether, these findings suggested
that weak suboptimal stimulation with weak aGalCer agonists
induced a pattern of cytokine secretion that was similar to that
associated with the iNKT cell response to self lipid(s).
An in vitro system for assessment of NK cell
transactivation
Studies of mouse iNKT cell responses have indicated that the
strong IFNc production resulting from stimulation with KRN7000
and other strong iNKT cell agonists originates from the secondary
activation of NK cells to secrete IFNc [11;17;19;41], in addition to
iNKT cell –derived IFNc. This suggested that a significant
component of the cytokine polarization of responses to iNKT cell
activating glycolipids in vivo depends on the extent to which IFNc
and potentially other proinflammatory cytokines are produced by
other leukocytes that undergo transactivation downstream of the
initial iNKT cell stimulation. To model this important component
of the overall response for human iNKT cell responses, we
developed an in vitro assay to assess the ability of human iNKT cells
to transactivate NK cells for IFNc production.
While mouse iNKT cells activated with KRN7000 are well
documented to induce IFNc production by NK cells
[11;17;19;41], this has not previously been shown to be the case
with human iNKT cells. Thus, although augmentation of NK cell
cytolytic activity has been observed in human cell cultures
following iNKT cell stimulation with KRN7000 [42–44], NK cell
cytokine production has not to our knowledge been studied. Using
fresh human PBMCs co-cultured with aGalCer analogs and
CFSE-labelled iNKT cells, we were able to discriminate iNKT
cells from other cells in flow cytometric analysis without using
TCR-specific Abs or aGalCer-loaded CD1d tetramers, which
might fail to detect them due to TCR downregulation (Figure 6A).
The PBMCs were used as a source of physiological CD1d
+ APC
(i.e. monocytes, B cells and rare DCs), as well as a source of T, B
and NK cells which, can be potentially transactivated by iNKT
cells.
Preliminary experiments revealed that a detectable human NK
cell transactivation, monitored by intracellular IFNc staining,
could be induced by iNKT cells pre-activated with PMA/
Ionomycin. Peak levels of NK cell transactivation were observed
after 20–24 h, with an iNKT/PBMC ratio of 1/10 to 1/40 (not
shown). Furthermore, upon iNKT cell stimulation by KRN7000,
nearly all B cells and NK cells, but not T cells, became CD69
+.A
similar high degree of CD69 induction in B and NK cells was also
observed with the C20:2 analog, while iNKT cell stimulation with
analogs of weak potency induced intermediate levels of CD69
positivity in B and NK cells (not shown). Staining for intracellular
IFNc showed that iNKT cells already had substantial expression
of IFNc at 6 h, and this continued to increase at 24 h (not shown).
Production of IFNc was detectable at 24 h in NK cells, but not in
T cells or B cells (Figure 6A). Thus, this in vitro system allowed us to
observe that, in a manner comparable to what has been described
in vivo in mice [11;17;19;41], KRN7000-activated human iNKT
cells responded rapidly and induced a subsequent transactivation
of NK cells. This transactivation was characterized here by IFNc
induction, and fits with the previously reported ability to induce
cytolytic activity [42–44]. Preliminary studies of intracellular
cytokine expression revealed that iNKT cells were the major
producers of IL-13, IL-4 and GM-CSF in this co-culture system
(not shown), and these cytokines were not detected by intracellular
staining in transactivated cells.
Factors controlling NK cell transactivation by human iNKT
cells
Using this in vitro system, we examined some of the potential
factors that may lead to NK cell transactivation. Previous
investigations in mice suggested that NK cells are activated to
secrete IFNc by IL-12 released from APC in response to CD40L
expression by iNKT cells [11], with a significant contribution also
attributable to iNKT cell-derived IFNc [41]. In addition, it was
recently described that mouse NK cells require IL-18 sensitization
to become responsive to IL-12 [45], and studies with human
iNKT cells have implicated IL-2 and IFNc in the stimulation of
the cytolytic activity of NK cells [42–44]. However, the role of
iNKT cell-derived IL-2 and IFNc to stimulate NK cell secretion of
IFNc has not been determined. We therefore tested whether IL-2,
IFNc, CD40L, IL-12 and IL-18 were involved in the process of
NK cell transactivation as a result of iNKT cell activation, in our
in vitro system. We observed a dose-dependent upregulation of
CD40L by iNKT cells (Figure 6B) which correlated with the level
of iNKT cell activation (assessed by intracellular IFNc staining).
This appeared to correlate with the agonistic potential of the
analog tested, as CD40L and IFNc were also induced with high
doses of the weak adamantanoyl agonist (Figure 6B). The degree of
NK cell transactivation correlated well with both the degree of
CD40L expression by iNKT cells and the degree of IFNc
secretion by iNKT cells, suggesting that CD40L and IFNc
expression by iNKT cells indeed contributed to NK cell
transactivation. Moreover, the specific blockade of IL-2, IFNc,
CD40L, IL-12 or IL-18 with mAbs decreased the NK cell
transactivation mediated by KRN7000 stimulation (Figure 6C).
While blocking of IFNc and CD40L had no effect on the
activation iNKT cell, either IL-2, IL-12 or IL-18 blockade
decreased the duration of iNKT cell production of IFNc after
48 h. This suggested that iNKT cells are sustained by a
‘‘feedback’’ loop involving IL-12 and IL-18, presumably derived
from APCs, and IL-2 in an autocrine manner. Also IL-13 levels
detected in supernatants appeared to be decreased upon IL-2 and
IL-18 blocking (not shown). Interestingly, the specific blocking of
any factor tested led to a detectable decrease of NK cell
transactivation (Figure 6C). Whereas neutralization of IFNc, IL-
2, CD40L and IL-18 showed a partial blocking effect, IL-12
blockade completely abolished the NK cell transactivation. These
blocking effects translated to a decrease in the overall IFNc
secreted in supernatants (not shown).
Failure of weak iNKT cell agonists to induce NK cell
transactivation
Comparison of aGalCer analogs with KRN7000 in the
transactivation assay at a fixed concentration (100 nM) showed
concentrations of other analogs (156, 1250 and 10000 nM, gray background bars). Data presented in this figure were interpreted from results shown
in Figure 2, and IL-13/IFNc & IL-4/IFNc ratios calculated for HDD3 and HDE3 clones with DCs are presented in supplementary Figure S6.
doi:10.1371/journal.pone.0014374.g005
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PLoS ONE | www.plosone.org 10 December 2010 | Volume 5 | Issue 12 | e14374Figure 6. A novel in vitro ‘‘transactivation assay’’ to assess the ability of human iNKT cells to activate other leukocytes. (A) Format for
analysis of transactivation of bystander leukocytes. Flow cytometric analysis was carried out for culture containing iNKT cells co-cultured for 24 hours
with fresh human PBMC at a 1/10 ratio. For the intracellular detection of IFNc, Brefeldin A was added for the last 4 hours. Representative electronic
gating is shown for the discrimination of CFSE-labeled iNKT cells, B cells, T cells, and NK cells to measure IFNc expression (or CD69 expression, not
shown). Filled black histograms show staining with vehicle control and are overlaid with open gray histograms for stimulation with 100 nM of
KRN7000. (B) Dose-dependent IFNc and CD40L expression by iNKT cells (top and middle graph, respectively) and IFNc production by transactivated
NK cells (bottom graph), after 24 h of co-culture of CFSE-labeled iNKT cells and PBMCs at a 1/10 ratios and the indicated concentration of either
KRN7000 (black filled circles) or the adamantanoyl (AD) analog (open circles). Data are presented for a CD4
+ clone (HDD3), and similar results (not
shown) were obtained with a DN clone (HDE3). (C) Effect of specific blockade of various cytokines and CD40L on the activation of iNKT cells and
transactivated NK cells. CFSE-labeled iNKT cells and PBMCs were co-cultured at a 1/40 ratio for the indicated time, in the presence of KRN7000 at
25 nM and 10 mg/mL of isotype matched control or specific blocking antibodies as indicated. Average percentages of IFNc
+ iNKT cells and NK cells,
assessed by intracellular staining at 24, 48 and 66 hours, are indicated in the left and right plots, respectively. Values significantly decreased as
compared to isotypic control are indicated with asterisks (P,0.05 in 2-way ANOVA).
doi:10.1371/journal.pone.0014374.g006
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higher ability to activate iNKT cells and stimulate NK cell
transactivation (Figure 7A). This translated into a high global
production of IFNc in association with high IL-13 levels. This also
correlated with detectable IL-12 generation and enhanced IL-18
levels compared to vehicle control. Multiple other aGalCer
Figure 7. Comparison of aGalCer analogs for their ability to induce NK cell transactivation. (A) iNKT cell clones were co-cultured for
24 hours with fresh human PBMC at a 1/10 ratio with 100 nM of the indicated analogs, and Brefeldin A was added for the last 4 hours. The
percentages of IFNc
+ iNKT cells (open bars) and IFNc
+ NK cells (filled bars) are indicated. Cytokine levels were assessed by ELISA in supernatants from
identical conditions in absence of Brefeldin A treatment: (B) IFNc levels (open bars) and IL-13 levels (filled bars); the detection limit was 82.3 ng/mL for
both cytokines. (C) IL-12 levels (open bars) and IL-18 levels (filled bars); the detection limit was 27.4 ng/mL. Results obtained with a CD4
+ clone
(HDD3) are presented, and similar data (not shown) were obtained with a DN clone (HDE3).
doi:10.1371/journal.pone.0014374.g007
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displayed a comparable pattern (not shown). On the other hand,
weak agonists, such as the lyso, difluorobenzoyl, bromobenzoyl
and adamantanoyl analogs, induced a lower degree of iNKT cell
activation with a limited transactivation of NK cells. This
translated into lower global IFNc production and lower, but still
detectable, IL-13 levels, while IL-12 was undetectable and IL-18
levels remained low. Altogether, the ability of iNKT cells to
transactivate NK cells appeared to correlate with the agonistic
potency of aGalCer analogs, with agonists of strong or
intermediate potency generating subsequent NK cell transactiva-
tion, while weak agonists partially activated iNKT cells and led to
limited or no NK cell transactivation.
Discussion
In the current study, the analysis in vitro of human iNKT cell
responses to cytokine polarizing aGalCer analogs defined in
mouse (e.g. OCH, C20:2 and C-glycoside) and the identification of
new analogs with N-aromatic branching have allowed us to define
different states of human iNKT cell activation. The lowest
detectable activation state of human iNKT cells was characterized
by IL-13 and GM-CSF secretion, as previously observed in studies
of the autoreactivity of these T cells against DCs and monocytes
[13;14;46] or in response to CD1d transfected cells (this work and
[13;31;47;48]. Using CD1d-transfected Hela cells and dendritic
cells as APCs, this pattern could be induced by using either
suboptimal doses (,1 nM) of strong agonists such as KRN7000 or
the C20:2 analog, or by using higher doses of weak agonists with
N-aromatic branching (,100 nM). Importantly, this was achieved
in cultures of cloned iNKT cells which did not allow the
recruitment of responses resulting from the transactivation of
NK cells. These results indicate that it is possible to manipulate
human iNKT cell responses using synthetic glycolipids in a
manner that mimics or even enhances the response to self-derived
natural antigens presented by CD1d
+ APCs. This function might
correspond to a physiological ‘‘steady state’’ or default regulatory
function, in absence of direct TCR recognition of microbial or
synthetic glycolipids presented by CD1d and in absence of IL-12
and IL-18 or type I IFN co-stimulation provided by activated
APCs [13;15].
In contrast, a distinct and apparently higher state of iNKT cell
activation was achieved by using either standard doses of strong
agonists (,100 nM) or high doses of weak agonists (i.e.
.400 nM). This was characterized by maximal IL-13 production
by human iNKT cells, along with high production of IFNc and
induction of IL-4 secretion. Importantly, this correlated with
transactivation of NK cells which contributed to a much higher
global IFNc secretion, and thereby biasing to a more Th1
polarized response. The distinction between a low versus high
degree of iNKT cell activation might rely on the ability of analogs
to form stable glycolipid/CD1d complexes and also on the affinity
of the iNKT cell TCR for these glycolipid/CD1d complexes [31].
These properties would lead to long lasting iNKT/APC
interaction [13;31], resulting in augmented intracellular calcium
signaling and ERK phosphorylation [13]. Such enhanced TCR
signaling in iNKT cells appears to be required for their secretion
of IFNc, IL-4 and IL-2 secretion from human iNKT cells [13] and
possibly also for the secondary transactivation of NK cells based
on findings from our study.
Our results obtained using human CD1d tetramers to measure
the avidity of equilibrium binding (KD), as well as studies of
tetramer binding kinetics, suggested that the biasing of iNKT cell
cytokine responses to selective IL-13 secretion observed with the
N-aromatic branching analogs of aGalCer can be explained by
low iNKT cell TCR avidity. However this does not exclude the
possibility that other mechanisms may also contribute to the
nature of the iNKT cell response that is triggered by these
compounds. For example, these weak analogs might be preferen-
tially loaded at the cell surface rather than at intracellular sites,
and they might be excluded from CD1d molecules positioned in
detergent-resistant plasma membrane microdomains, both of
which are mechanisms that we have previously identified to alter
the quality of the iNKT cell responses in mice [17;26]. Additional
studies will be required to test this possibility. It is important to
note that results from the current study clearly imply that IFNc
production by human iNKT cells occurred at a lower threshold of
activation than IL-4 production, indicating that a selective
polarization of iNKT cells to IL-4 production without IFNc
secretion might not be possible for human iNKT cells. This
contrasts with previous findings from one study of mouse iNKT
cells, for which IFNc production was reported to require a
stronger TCR activation signal than IL-4 as a result of a signaling
mechanism involving c-rel expression [24]. Although this may
represent a significant functional difference between mouse and
human iNKT cells, our data suggest that it may still be possible to
effectively polarize human iNKT cells to a ‘‘Th2-like profile’’
characterized by IL-13 production, instead of IL-4 production.
The preferential production of IL-13 by human iNKT cells
activated with weak agonists may have important implications in the
therapeutic manipulation of these cells for treatment of autoimmu-
nity or other inflammatory conditions. Since the range of
immunologic effects of IL13 may not overlap completely with those
of IL-4 [49], it will be critical to determine the potential benefit
provided by responses biased toward IL-13 production in the
context of autoimmune disease. For example, since IL-13 might
generate adverse effects, such as induction of allergy or asthma [50],
and a profibrotic effect of IL-13 secreted by hepatic iNKT cells has
beensuggested inthecontextof chronicHCV infection [51].Onthe
other hand, additional studies are necessary to determine whether
IL-13 might stimulate potentially beneficial immunosuppressive
activity by inducing alternatively activated (M2) macrophages with
anti-inflammatory properties [52;53] or by inducing TGFb
production from immature myeloid cells, as was described for
responsesofnon-invariantNKTcellsintumorbearingmice[54;55].
In the current study we also describe a new in vitro assay to
determine the ability of human iNKT cells activated by glycolipid
antigens to transactivate other leukocytes, especially induction of
IFNc production by NK cells, which can contribute in a major way
to IFNc in the setting of iNKT cell responses in mice [17;19;41].
Our data suggest that human NK cells can effectively be
transactivated by human iNKT cells in a similar manner to that
described in mouse and that this is correlated with a high degree of
iNKT cell activation. Consistent with previous mouse data, this
process involved CD40L upregulation and secretion of IFNc and
IL-2 by iNKT cells, as well as IL-12 and IL-18, probably derived
from APC upon CD40 signaling [56]. While human iNKT cell-
derived IL-2/IFNc are known to induce cytolytic activity from NK
cells [42–44], we show here that these cytokines are also involved in
the induction of IFNc secretion by human NK cells. To our
knowledge, we describe for the first time the ability of activated
iNKT cellsto induceIL-18 releaseand suggest that humanNK cells
might require sensitization by IL-18 to respond to IL-12 in the
manner that has been documented for mouse NK cells [45]. In
addition, the induction of IL-12 and IL-18 in our system appeared
to sustain iNKT cell expression of IFNc and fits with the previously
described responsiveness of iNKT cells to these cytokines
[13;15;16;57].
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require comparison with in vivo data generated in non-human
primates or in human clinical studies. This is required to
determine the physiological relevance this new assay. To date
the activity of KRN7000 in humans has been tested only in cancer
patients, who are known to display numerical and/or functional
iNKT cell defects [12]. To our knowledge, KRN7000 and its
structural analogs have never been tested in healthy humans.
More effort is thus needed to better evaluate iNKT cell responses
in experimental systems that may adequately model human
immune responses in vivo. For example, this could involve testing
the effects of analogs in non-human primates or in humanized
mouse models (e.g., mice engineered to express human CD1d and
adoptively transferred with human iNKT cells). Importantly, our
data are suggestive that the clinical use of polarizing analogs
should consider the possibility that some analogs might induce
distinct, species-dependent reactivity, as previously observed with
synthetic antigens or microbial analogs [17;20;28–30;32;33]. We
here confirmed that human iNKT cells display a low reactivity in
vitro to OCH [17;20] and C-glycoside [28;29], and our novel
transactivation assay unexpectedly suggested that the C20:2
analog can induce a KRN7000-like profile, at least in vitro. These
findings are in general agreement with most previously reported
studies on the in vitro reactivity of human iNKT cell clones to
various aGalCer analogs [20;26;30;31].
A number of published observations have suggested that
significant differences may exist between mouse and human
iNKT cells in terms of their responses to synthetic and natural
glycolipid antigens. Human and mouse CD1d proteins have been
shown to have distinct abilities to bind or present certain
glycolipids, such as OCH [20;26], non-glycosidic derivatives of
aGalCer [30] and diacylated glycerol based glycolipids derived
from Borrelia [32;33]. Furthermore, analogs with unsaturated N-
acyl chains showed a KRN7000-like cytokine response in human
in vitro systems (this work and [17;20;26], while they are Th2-
polarizing in mouse [17]. Although not yet investigated in detail, it
is possible that these differences could be due to intrinsic
differences between mouse and human CD1d proteins. The
sequence homology of the antigen binding a1 and a2 domains
shows only a moderate level of conservation between the two
species, while mouse and human CD1d have distinct ability to
present diacylated glycerol based glycolipids derived from Borrelia
[33]. It is also particularly notable that the tyrosine-based motif in
the human CD1d cytoplasmic tail lacks the ability to bind the
cytosolic adaptor protein complex AP-3, which is responsible for
the sorting of mouse CD1d into late endosomal and lysosomal
compartments [1;58]. Based on findings in the current study, we
propose that structural analogs of aGalCer with N-linked aromatic
branching and weak iNKT cell agonist activity might represent
promising candidates for further development as immunomodu-
latory agents for treatment of autoimmune or inflammatory
diseases in humans. Because of the importance of ensuring fine
tuning of in vivo iNKT cell responses in the treatment of such
diseases, such an approach using synthetic glycolipids will need to
be evaluated carefully with models that closely approximate the
human immune response.
Supporting Information
Figure S1 Cytokine responses of human iNKT cell clones to
CD1d-transfected HeLa cells. CD1d-transfected HeLa cells were
used as APC for iNKT cell stimulation in the absence of added
glycolipids. After 24h of co-culture, supernatants were harvested,
and cytokine levels were measured by ELISA. The sensitivity of
detection was 82.3 pg/mL for GM-CSF (white bars), IL-13 (black
bars) and IFNc (hatched bars). The data are shown for a variety of
clones indicated at the bottom of the graph. No detectable
reactivity was observed with mock-transfected HeLa cells (not
shown).
Found at: doi:10.1371/journal.pone.0014374.s001 (0.32 MB TIF)
Figure S2 Cytokine responses of a DN iNKT cell clone to a dose
range of aGalCer analogs. The data shown were generated with
the double negative (DN) HDE3 clone in the same manner as
presented in Figure 2 for the CD4+ iNKT cell clone (HDD3).
Found at: doi:10.1371/journal.pone.0014374.s002 (0.12 MB TIF)
Figure S3 Cytokine responses of a CD8a+ iNKT cell clone to a
dose range of aGalCer analogs. The data shown were generated
with the CD8a+ clone HDA7, in the same manner as presented in
Figure 2 for the CD4+ iNKT cell clone (HDD3).
Found at: doi:10.1371/journal.pone.0014374.s003 (0.12 MB
TIF)
Figure S4 Human iNKT cell clone reactivity to OCH and C-
Glycoside. (A) CD1d-transfected HeLa cells were incubated
overnight with increasing concentrations of KRN7000 (ranging
from 0.05 to 100 nM) and OCH or C-Glycoside (ranging from
39 nM to 10 mM) and then used as APC for iNKT cell
stimulation. After 24 h of co-culture, supernatants were harvested,
and cytokine levels were measured by ELISA. The sensitivity of
detection was 27.4 pg/mL for IL-4 and 82.3 pg/mL for IL-13 and
IFNc. The data shown were generated with a CD4+ iNKT cell
clone (HDD3), as well as a double negative (DN, HDE3). Dose-
response curves are presented for IFNg, IL-4 and IL-13 (top to
bottom panels respectively). Mean values measured from triplicate
wells are indicated, and standard deviations are shown with
brackets. Symbols for each glycolipid are indicated in the legend.
(B) The same iNKT cell clones were stained with titrated amounts
of analog-loaded hCD1d tetramers (1, 2.5, 5, 10, 20 and 40 nM
final concentration), and the measured MFI is plotted for OCH-
loaded tetramers (open inverted triangles) and C-Glycoside-loaded
tetramers (black diamonds).
Found at: doi:10.1371/journal.pone.0014374.s004 (0.13 MB TIF)
Figure S5 Comparison of cytokine responses of human iNKT
cell clones between CD1d-transfected HeLa cells and Dendritic
Cells, with a limited range of analog concentrations. CD1d-
transfected HeLa cells (black bars) and monocyte-derived DCs
(white bars) were incubated overnight in parallel with increasing
concentrations of KRN7000, C20:2 (tested from left to right at 0.1,
1, 10 and 100 nM,) and higher concentrations of other analogs
(10, 100 nM, 1 and 10 mM), then used as APC for iNKT cell
stimulation. After 24 h of co-culture, supernatants were harvested,
and cytokine levels were measured by ELISA. The sensitivity of
detection was 27.4 pg/mL for IL-4 and 82.3 pg/mL for IL-13 and
IFNc. The data shown were generated with a CD4+ iNKT cell
clone (HDD3) and a double negative (DN, HDE3).
Found at: doi:10.1371/journal.pone.0014374.s005 (0.12 MB
TIF)
Figure S6 Dose-dependent cytokine polarization of human
iNKT cells with DCs. Variations in cytokine ratios depending
on the analog concentration tested, IL-13/IFNc ratios and IL-4/
IFNc ratios are presented on the bottom and top panel,
respectively (calculated as explained in Materials and Methods).
Ratios could be calculated only when IL-4 and/or IFNc were
detectable and the # symbol indicates ratios which could not be
calculated. Concentrations of antigens are indicated as in
Supplementary Figure S5, with low concentrations tested for
KRN7000, C20:2 (0.1, 1, 10 and 100 nM) and high concentra-
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in this figure were interpreted from results shown in Supplemen-
tary Figure S5, and IL-13/IFNc & IL-4/IFNc ratios calculated for
HDD3 (left panel) and HDE3 (right panel) clones with DCs are
presented.
Found at: doi:10.1371/journal.pone.0014374.s006 (0.13 MB TIF)
Figure S7 Cytokine responses of human iNKT cell clones to a
dose range of aGalCer analogs and costimulation by IL-12/IL-18.
CD1d-transfected HeLa cells were incubated overnight with the
indicated concentrations of KRN7000 and aGalCer analogs
(concentration selected to provide suboptimal stimulation) and
then used as APC for iNKT cell stimulation in absence (open bars)
or presence of IL-12 and IL-18 (10 ng/mL and 50 ng/mL
respectively, black bars). After 24 h of co-culture, supernatants
were harvested, and cytokine levels were measured by ELISA.
Average cytokine levels and standard deviations are indicated. The
sensitivity of detection was 27.4 pg/mL for IL-4 and 82.3 pg/mL
for IL-13, GM-CSF and IFNc. The data shown were gener-
ated with a CD4+ iNKT cell clone (HDD3), and similar data
(not shown) were obtained with a double negative clone (DN,
HDE3).
Found at: doi:10.1371/journal.pone.0014374.s007 (0.11 MB TIF)
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